Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of HSK39297 Tablets in Patients With Lupus Nephritis
Haisco Pharmaceutical Group Co., Ltd.
105 participants
Nov 18, 2025
INTERVENTIONAL
Conditions
Summary
A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
once daily, oral administration of HSK39297 tablets 200mg from Day 1 to Week 52.
once daily, oral administration of HSK39297 tablets 300mg from Day 1 to Week 52.
once daily, oral administration of placebo from Day 1 to Week 52.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07363460